OECD (External organisation)

  • Elisabeth 't Hoen (Member)
  • Sammi-Jo Perehudoff (Member)
  • Daniela Moye Holz (Member)
  • Marie Elske Gispen (Member)
  • Toebes, B. (Member)
  • Hogerzeil, H. (Member)

Activity: MembershipAcademic


Joint Submission to OECD Online Consultation ‘Sustainable access to innovative therapies’

Excessively high prices of innovative medicines threaten patient access and health system sustainability in developing and industrialised countries alike. The Organisation for Economic Co-operation and Development (OECD) has launched a new initiative to facilitate high-level dialogue between stakeholders on access to innovative medicines and the sustainability of prices. On April 30, 2017, members of the GHLG Research Centre and the Global Health Unit in the Dept. of Health Sciences at the University Medical Centre Groningen responded to OECD’s online consultation for sustainable access to innovative medicines. Here are excerpts from our response.
Held atOECD, France


  • access to medicines
  • expensive medicines
  • equitable access